Publications

About "anle 138b"

• The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils.
Publication published on NATURE COMMUNICATIONS.

Please follow this link for the complete publication.

• Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial.
Publication published on THE LANCET - eBioMedicine.

Please follow this link for the complete publication.

• Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• Anle138b Modulates α-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.
Publication published on Wiley Online Library.

Please follow this link for the complete publication.

• Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau.
Publication published on PubMed.gov.

Please follow this link for the complete publication.

About "qRT-QuIC"

• Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.
Publication published on PubMed Central.

Please follow this link for the complete publication.

• Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.
Publication published on PubMed.gov.

Please follow this link for the complete publication.

About PET tracer development

• [ ¹¹ C]MODAG-001-towards a PET tracer targeting α-synuclein aggregates.
Publication published on PubMed.gov.

Please follow this link for the complete publication.

• ¹¹ C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson's Disease That Binds to α-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.
Publication published on on PubMed.gov.

Please follow this link for the complete publication.